Unknown

Dataset Information

0

Enhanced BNT162b2 vaccine-induced cellular immunity in anti-CD19 CAR T cell-treated patients.

ABSTRACT:

SUBMITTER: Oh BLZ 

PROVIDER: S-EPMC9281508 | biostudies-literature |

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Transcriptomics Comparation of the anti-CD19 CAR-T and the NMN treated anti-CD19 CAR-T
2023-04-01 | GSE200367 | GEO
Unknown Modeling anti-CD19 CAR T cell therapy in humanized mice with human immunity and autologous leukemia.
| S-EPMC6354733 | biostudies-literature
Transcriptomics Synergically enhanced anti-tumor immunity of in vivo CAR by vaccination-elicited antibody-mediated cellular cytotoxicity boosting
2024-05-22 | GSE268105 | GEO
Unknown Waning Immunity after the BNT162b2 Vaccine in Israel.
| S-EPMC8609604 | biostudies-literature
Unknown A safe and potent anti-CD19 CAR T cell therapy.
| S-EPMC7518381 | biostudies-literature
Unknown Development of CMV-CD19 bi-specific CAR T cells with post-infusion in vivo boost using an anti-CMV vaccine.
| S-EPMC8475363 | biostudies-literature
Unknown CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies.
| S-EPMC7885572 | biostudies-literature
Unknown Simplified process for the production of anti-CD19-CAR-engineered T cells.
| S-EPMC4141724 | biostudies-literature
Unknown Anti-CD19 CAR T cells potently redirected to kill solid tumor cells.
| S-EPMC7971483 | biostudies-literature
Unknown BNT162b2 mRNA COVID-19 vaccine Reactogenicity: The key role of immunity.
| S-EPMC8580836 | biostudies-literature